Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
COLUMBUS, Ohio, Aug. 30, 2016 -- Cleobrothers & Co., Inc. announced that it has recently opened a sales and marketing office in Salvador, Bahia, Brazil as part of its global expansion plan for promoting and distributing pharmaceuticals and hi-tech medical devices in South America, Asia, Africa and the Middle East.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dcf12437-65fb-4d2f-a34d-6246da1f7ec6
According to Mr. Innocent Nweze, CEO of Cleobrothers and Co. Inc., “With a population exceeding 200 million people, Brazil provides tremendous potential for launching our brand of over-the-counter medications to retail and medical markets.”
The company currently has a portfolio of over-the-counter (OTC) cold relief and decongestant medications and over 80 Specialty Dermatology/Personal Skin Care Products that are specially formulated for tropical climates.
In addition, Cleobrothers offers a pipeline of two first-in-class technologies -- a 24/7 proprietary Pregnancy Monitoring device and a new Combination Pharmaceutical for management of Type-2 Diabetes. Both technologies are currently in clinical trials with product launches planned for the first quarter of 2017.
The new office will be located at Av. Tancredo Neves, 450-15° andar, 16th Floor, Caminho das Árvores Salvador, BA 41819-900, Brazil. Phone: +55 (71) 3340-0600.
“Having access to U.S. manufactured and FDA approved medications adds a strong competitive advantage to our sales and marketing efforts in Brazil,” Mr. Nweze added.
The Brazilian office opening comes on the heels of the company’s recent announcement of a joint venture agreement with PGC Solutions, Ltd. to distribute, market and promote Cleobrothers branded products in Nigeria.
Cleobrothers & Co., Inc. is a Columbus based biotechnology company focused on researching and developing medical and healthcare innovations that are dedicated to helping people worldwide live better lives.
For more information about Cleobrothers and Co., Inc. visit www.cleobrothers.com
(Office Photo attached)
Contact: Innocent Nweze email: [email protected] Phone: 614.934.1367
